835 related articles for article (PubMed ID: 25994980)
1. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
[TBL] [Abstract][Full Text] [Related]
2. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
3. Mannitol/l-Arginine-Based Formulation Systems for Freeze Drying of Protein Pharmaceuticals: Effect of the l-Arginine Counter Ion and Formulation Composition on the Formulation Properties and the Physical State of Mannitol.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2016 Oct; 105(10):3123-3135. PubMed ID: 27506270
[TBL] [Abstract][Full Text] [Related]
4. Arginine as an Excipient for Protein Freeze-Drying: A Mini Review.
Stärtzel P
J Pharm Sci; 2018 Apr; 107(4):960-967. PubMed ID: 29183741
[TBL] [Abstract][Full Text] [Related]
5. Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations.
Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
Eur J Pharm Biopharm; 2020 Feb; 147():45-56. PubMed ID: 31866444
[TBL] [Abstract][Full Text] [Related]
6. Fundamentals of freeze-drying.
Nail SL; Jiang S; Chongprasert S; Knopp SA
Pharm Biotechnol; 2002; 14():281-360. PubMed ID: 12189727
[TBL] [Abstract][Full Text] [Related]
7. Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins III: collapse during storage at elevated temperatures.
Schersch K; Betz O; Garidel P; Muehlau S; Bassarab S; Winter G
Eur J Pharm Biopharm; 2013 Oct; 85(2):240-52. PubMed ID: 23727369
[TBL] [Abstract][Full Text] [Related]
8. Significant Drying Time Reduction Using Microwave-Assisted Freeze-Drying for a Monoclonal Antibody.
Gitter JH; Geidobler R; Presser I; Winter G
J Pharm Sci; 2018 Oct; 107(10):2538-2543. PubMed ID: 29890173
[TBL] [Abstract][Full Text] [Related]
9. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation.
Chang BS; Beauvais RM; Dong A; Carpenter JF
Arch Biochem Biophys; 1996 Jul; 331(2):249-58. PubMed ID: 8660705
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the sucrose/glycine/water system by differential scanning calorimetry and freeze-drying microscopy.
Kasraian K; Spitznagel TM; Juneau JA; Yim K
Pharm Dev Technol; 1998 May; 3(2):233-9. PubMed ID: 9653761
[TBL] [Abstract][Full Text] [Related]
11. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.
Abdul-Fattah AM; Truong-Le V; Yee L; Nguyen L; Kalonia DS; Cicerone MT; Pikal MJ
J Pharm Sci; 2007 Aug; 96(8):1983-2008. PubMed ID: 17286290
[TBL] [Abstract][Full Text] [Related]
12. Freeze drying of nanosuspensions, 2: the role of the critical formulation temperature on stability of drug nanosuspensions and its practical implication on process design.
Beirowski J; Inghelbrecht S; Arien A; Gieseler H
J Pharm Sci; 2011 Oct; 100(10):4471-81. PubMed ID: 21607957
[TBL] [Abstract][Full Text] [Related]
13. Development of freeze-dried biosynthetic Factor VIII: I. A case study in the optimization of formulation.
Jameel F; Tchessalov S; Bjornson E; Lu X; Besman M; Pikal M
Pharm Dev Technol; 2009; 14(6):687-97. PubMed ID: 19883259
[TBL] [Abstract][Full Text] [Related]
14. Physical characterisation of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage.
Passot S; Fonseca F; Alarcon-Lorca M; Rolland D; Marin M
Eur J Pharm Biopharm; 2005 Aug; 60(3):335-48. PubMed ID: 15894475
[TBL] [Abstract][Full Text] [Related]
15. Effect of Arginine on the Aggregation of Protein in Freeze-Dried Formulations Containing Sugars and Polyol: 1-Formulation Development.
Hackl E; Darkwah J; Smith G; Ermolina I
AAPS PharmSciTech; 2018 Feb; 19(2):896-911. PubMed ID: 29047017
[TBL] [Abstract][Full Text] [Related]
16. Excipients for Room Temperature Stable Freeze-Dried Monoclonal Antibody Formulations.
Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
J Pharm Sci; 2020 Jan; 109(1):807-817. PubMed ID: 31622600
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the stabilisation of freeze-dried lysozyme and the physical properties of the formulations.
Liao YH; Brown MB; Martin GP
Eur J Pharm Biopharm; 2004 Jul; 58(1):15-24. PubMed ID: 15207533
[TBL] [Abstract][Full Text] [Related]
18. Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying.
Jovanović N; Bouchard A; Hofland GW; Witkamp GJ; Crommelin DJ; Jiskoot W
Eur J Pharm Sci; 2006 Mar; 27(4):336-45. PubMed ID: 16338123
[TBL] [Abstract][Full Text] [Related]
19. The Influence of Arginine and Counter-Ions: Antibody Stability during Freeze-Drying.
Seifert I; Bregolin A; Fissore D; Friess W
J Pharm Sci; 2021 May; 110(5):2017-2027. PubMed ID: 33316241
[TBL] [Abstract][Full Text] [Related]
20. Measurement of the kinetics of protein unfolding in viscous systems and implications for protein stability in freeze-drying.
Tang XC; Pikal MJ
Pharm Res; 2005 Jul; 22(7):1176-85. PubMed ID: 16028019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
